Form D · Pharmaceuticals
Tiburio Therapeutics Inc.
Cambridge, MA · CIK 0001763894
Offering snapshot reported Jan 8, 2019 · SEC filing
- Reported sold
- $5M Offering amount: $31M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 20, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 8, 2019 | Initial | $5,000,001 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-329946
Source: Form D, filed Jan 8, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christoph M. Adams | Director, Executive |
| Sandip Agarwala | Director |
| Mette Kirstine Agger | Director |
| Abraham N. Ceesay | Executive |
| James G. Mc Arthur | Executive |
| David Mott | Director |
| Sara Nayeem | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
700 Technology Square 3 Rd Floor
Cambridge, MA, 02139
Cambridge, MA, 02139